Apixaban, a direct oral anticoagulant (DOAC) that selectively inhibits factor Xa, is widely used for stroke prevention in nonvalvular atrial fibrillation and for the treatment and prevention of deep vein thrombosis and pulmonary embolism [2]. This evidence concerns the gene F10 and deep vein thrombosis.